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Abstract	  
Background:	  Alterations	  in	  the	  fibroblast	  growth	  factor	  receptor	  (FGFR)	  tyrosine	  kinase	  have	  been	  found	  in	  cancers	  such	  as	  glioblastoma	  multiforme,	  breast	  cancer,	  bladder	  cancer,	  cholangiocarcinoma,	  prostate	  cancer,	  thyroid	  cancer,	  oral	  cancer,	  and	  lung	  cancer.	  Advances	  in	  sequencing	  technology	  and	  small	  molecule	  inhibitors	  allow	  for	  matching	  patients	  with	  targeted	  therapies	  of	  tyrosine	  kinases.	  However,	  despite	  initial	  response	  to	  therapy,	  patients’	  cancers	  soon	  become	  resistant	  to	  inhibitors	  over	  time	  and	  develop	  acquired	  resistance.	  We	  will	  be	  using	  protein	  arrays	  and	  Western	  blot	  analysis	  to	  understand	  acquired	  secondary	  resistance	  mechanisms	  to	  tyrosine	  kinase	  inhibitors	  used	  in	  cancer	  treatments.	  The	  RT-­‐4,	  a	  bladder	  cancer	  cell	  line	  with	  a	  FGFR3-­‐TACC3	  fusion	  will	  be	  used	  as	  model	  for	  resistance	  to	  the	  FGFR	  tyrosine	  kinase	  inhibitors	  Ponatinib	  and	  BGJ398.	  
Methods:	  Over	  a	  period	  of	  one	  year	  the	  cell	  line	  RT-­‐4	  was	  exposed	  to	  increasing	  dosages	  of	  BGJ398	  and	  Ponatinib.	  RT-­‐4	  cell	  lines	  became	  less	  sensitive	  to	  the	  drug,	  and	  they	  were	  determined	  to	  be	  resistant	  while	  demonstrating	  a	  two-­‐log	  fold	  difference	  in	  cell	  viability	  compared	  to	  the	  parental	  RT-­‐4	  cell	  line.	  Reverse	  Phase	  Protein	  Array	  (RPPA)	  provides	  a	  broad	  assessment	  of	  proteins	  and	  signaling	  pathways.	  Further	  confirmation	  of	  the	  changes	  in	  protein	  expression	  between	  the	  parent	  and	  resistant	  cell	  lines	  was	  done	  by	  Western	  blot	  analysis	  in	  an	  attempt	  to	  identify	  a	  possible	  resistance	  mechanism.	  	  	  
Results:	  After	  resistant	  RT-­‐4	  cell	  lines	  were	  created,	  we	  identified	  the	  Akt	  pathway	  as	  a	  possible	  resistance	  mechanism	  by	  RPPA	  and	  confirmed	  by	  Western	  blot	  analysis.	  Combined	  treatment	  in	  resistant	  cell	  lines	  of	  FGFR	  inhibitor,	  BGJ3983,	  and	  Akt	  inhibitor,	  GSK2141795,	  was	  more	  effective	  in	  reducing	  cell	  viability	  than	  either	  inhibitor	  alone.	  The	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identification	  of	  the	  Akt	  signaling	  pathway	  as	  a	  secondary	  resistance	  mechanism	  can	  be	  a	  potential	  secondary	  inhibitor	  target.	  
Discussion:	  FGFR	  acquired	  resistance	  has	  not	  been	  studied	  and	  we	  identified	  the	  Akt	  pathway	  as	  one	  mechanism	  for	  resistance	  in	  cancers	  with	  FGFR	  fusions.	  RPPA	  analysis	  can	  be	  a	  useful	  tool	  for	  identifying	  candidate	  resistance	  pathways	  and	  targets.	  Combination	  treatment	  with	  FGFR	  and	  AKT	  inhibitors	  may	  be	  a	  more	  effective	  therapy	  than	  individual	  inhibitor	  treatment.	  	  
Introduction	  Genetic	  alterations	  in	  fibroblast	  growth	  factor	  receptors	  (FGFR)	  can	  occur	  through	  point	  mutations,	  gene	  fusions,	  or	  amplifications,	  leading	  to	  activation	  of	  FGFR	  signaling,	  which	  can	  result	  in	  diseases	  such	  as	  cancer.	  Thus,	  FGFR	  has	  recently	  become	  a	  novel	  target	  for	  new	  small	  molecule	  inhibitors	  that	  turn	  FGFR	  signaling	  off	  in	  cancer	  cells.	  However,	  despite	  initial	  responses	  to	  therapy,	  patients	  in	  clinical	  trials	  receiving	  novel	  FGFR	  inhibitors	  are	  expected	  to	  develop	  acquired	  resistance	  over	  time.	  Therefore,	  it	  is	  imperative	  that	  we	  understand	  acquired	  resistance	  to	  FGFR	  inhibitors	  so	  that	  we	  can	  develop	  rational	  combination	  treatments	  to	  overcome	  impending	  resistance.	  	  The	  predominant	  FGFR	  inhibitors	  are	  tyrosine	  kinase	  inhibitors.	  Tyrosine	  kinases	  (TK)	  are	  enzymes	  that	  transfer	  a	  phosphate	  to	  a	  tyrosine	  residue	  in	  polypeptides.	  They	  regulate	  a	  wide	  variety	  of	  cell	  functions	  including	  proliferation,	  survival,	  differentiation,	  function	  and	  motility.	  1	  TK	  can	  be	  receptor	  TKs,	  such	  as	  FGFRs,	  which	  are	  found	  in	  the	  cell	  membrane	  and	  bind	  ligands,	  or	  nonreceptor	  TKs,	  which	  are	  found	  in	  the	  cytosol,	  nucleus,	  and	  the	  inner	  surface	  of	  the	  plasma	  membrane.	  A	  receptor	  TK	  contains	  three	  parts:	  a	  N-­‐terminal	  lobe	  to	  bind	  ATP	  and	  magnesium,	  a	  C-­‐terminal	  lobe	  containing	  an	  activation	  loop,	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and	  a	  cleft	  to	  bind	  a	  polypeptide	  substrate.	  1	  When	  a	  receptor	  TK	  binds	  a	  ligand,	  it	  dimerizes	  and	  autophosphorylates.	  This	  reaction	  creates	  a	  binding	  site	  for	  signaling	  proteins	  downstream	  of	  the	  TK.	  Tyrosine	  phosphatases	  and	  inhibitory	  molecules	  often	  terminate	  the	  reaction.	  1	  	  	   FGFR	  is	  a	  classic	  example	  of	  a	  receptor	  TK	  and	  consists	  of	  a	  family	  including	  FGFR1,	  FGFR2,	  FGFR3,	  and	  FGFR4,	  and	  18	  FGF	  ligands	  that	  bind	  to	  the	  four	  receptors.	  2	  FGFR	  signals	  to	  a	  variety	  of	  downstream	  pathways,	  such	  as	  MAPK,	  STAT,	  and	  PI3K	  pathway,	  and	  helps	  to	  regulate	  cell	  growth.	  When	  FGFR	  is	  de-­‐regulated,	  through	  a	  variety	  of	  methods,	  cells	  can	  proliferate	  at	  an	  abnormal	  rate,	  which	  leads	  to	  diseases,	  such	  as	  cancer.	  Genetic	  alterations	  that	  de-­‐regulate	  FGFR	  include	  gene	  amplifications,	  translocations,	  and	  point	  mutations.	  2	  
	  	   Gene	  translocations	  can	  result	  in	  TK	  protein	  fusions.	  The	  fusion	  partner	  of	  the	  TK	  has	  several	  important	  functions	  that	  include	  stabilized	  structure,	  increased	  expression,	  loss	  of	  wild-­‐type	  expression,	  oligomerization	  activation,	  loss	  of	  inhibitory	  domains,	  and	  avoidance	  of	  degradation.	  3	  Many	  fusion	  partners	  can	  result	  in	  a	  direct	  or	  indirect	  oligomerization	  and	  constituently	  activated	  the	  TK,	  which	  results	  in	  the	  activation	  of	  proteins	  downstream	  and	  excessive	  cell	  proliferation.	  3	  Previous	  FGFR	  studies	  show	  that	  FGFR	  inhibitors	  have	  maximum	  potency	  on	  cell	  lines	  with	  high	  levels	  of	  wild-­‐type	  or	  mutant	  FGFR3	  expression.	  All	  three	  inhibitors,	  PD173074,	  TKI-­‐258,	  and	  SU5402,	  decreased	  downstream	  signaling,	  but	  had	  no	  effect	  in	  normal	  human	  urothelial	  cells.4	  Later	  studies	  have	  attributed	  high	  levels	  of	  sensitivities	  not	  only	  to	  the	  over-­‐expressed	  FGFR3	  protein,	  but	  to	  cell	  lines	  with	  FGFR	  fusions.5	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   To	  study	  acquired	  resistance	  to	  FGFR	  inhibitors,	  we	  have	  used	  a	  simplified	  cell	  line	  model.	  The	  cell	  line	  we	  will	  be	  using	  is	  RT-­‐4,	  which	  is	  a	  bladder	  cancer	  that	  has	  an	  FGFR3-­‐TACC3	  fusion.	  We	  decided	  to	  study	  acquired	  resistance	  in	  the	  RT-­‐4	  cell	  line	  with	  two	  FGFR3	  inhibitors,	  BGJ398	  and	  Ponatinib.	  Both	  BGJ398	  and	  Ponatinib	  are	  currently	  being	  used	  in	  clinical	  trials	  at	  OSU	  for	  patients	  with	  cancers	  that	  have	  FGFR	  alterations.	  BGJ398	  binds	  directly	  to	  the	  ATP	  binding	  site	  in	  FGFR,	  while	  Ponatinib	  binds	  to	  a	  site	  adjacent	  to	  the	  ATP	  pocket	  and	  causes	  a	  conformation	  change	  in	  FGFR.	  2,	  6	  After	  it	  was	  determined	  that	  we	  had	  established	  a	  RT-­‐4	  BGJ398	  resistant	  cell	  line	  and	  a	  RT-­‐4	  Ponatinib	  resistant	  cell	  line,	  we	  began	  to	  look	  at	  proteins	  that	  were	  upregulated	  and	  downregulated	  that	  may	  result	  in	  secondary	  resistance.	  These	  secondary	  resistance	  mechanisms	  are	  also	  possible	  therapeutic	  targets	  and	  could	  eventually	  be	  administered	  directly	  after	  resistance	  develops	  in	  patients.	  Using	  a	  variety	  of	  assays	  we	  will	  find	  a	  secondary	  resistant	  mechanism	  pathway,	  which	  will	  allow	  for	  a	  secondary	  inhibitor	  target	  and	  a	  decrease	  in	  cell	  viability	  in	  the	  resistant	  cell	  lines.	  
	  
Materials	  and	  Methods	  
	  
Cell	  Culture	  RT-­‐4	  cells	  were	  obtained	  from	  American	  Type	  Culture	  Collection	  (ATCC)	  and	  maintained	  in	  McCoy	  media	  supplemented	  with	  10%	  Fetal	  Bovine	  Serum	  and	  1%	  penicillin-­‐streptomycin.	  Ponatinib,	  BGJ398,	  and	  GSK2141795	  were	  purchased	  from	  Selleck	  Chemicals.	  Drug-­‐	  resistant	  RT-­‐4	  cells	  were	  generated	  by	  exposing	  the	  parental	  cell	  line	  to	  increasing	  concentrations	  of	  the	  Ponatinib	  and	  BGJ398	  until	  there	  was	  an	  approximate	  two	  logarithmic	  fold	  difference	  in	  the	  viability	  of	  the	  parental	  and	  resistant	  cell	  lines.	  	  	  
	   6	  
Viability	  Assay	  Both	  parental	  and	  resistant	  cell	  lines	  were	  plated	  in	  96-­‐well	  plates,	  with	  3x103	  cells	  per	  well,	  and	  24	  hours	  later	  exposed	  to	  a	  variety	  of	  drug	  concentrations	  ranging	  from	  50nM	  to	  15uM	  for	  72	  hours.	  Cell	  viability	  was	  determined	  by	  CellTiter-­‐Glo	  assay	  following	  the	  manufacturers	  protocol	  (Promega).	  Cell	  viability	  is	  calculated	  by	  setting	  the	  vehicle	  control	  at	  100%	  viability	  and	  calculating	  the	  viability	  of	  other	  concentrations	  as	  a	  ratio	  compared	  to	  the	  vehicle	  control.	  	  	  
Reverse	  phase	  protein	  array	  (RPPA)	  To	  extract	  protein,	  cells	  were	  lysed	  using	  Lysis	  Buffer	  (1%	  Triton	  X-­‐100,	  50mM	  HEPES	  pH	  7.4,	  150nM	  NaCl,	  1.5mM	  MgCl2,	  1mM	  EGTA,	  100mM	  Ma	  pyrosphoshpate,	  1mM	  Na3VO4,	  10%	  glycerol,	  and	  phosphatase	  and	  protease	  inhibitors)	  and	  after	  sonication,	  were	  centrifuged	  at	  4°C	  for	  10	  minutes	  at	  12,700×g.	  After	  protein	  concentrations	  were	  determined	  using	  Bio-­‐Rad	  Protein	  Assay	  Dye	  Reagent	  Concentrate	  and	  Nanodrop	  technology,	  the	  lysate	  was	  mixed	  with	  4×	  SDS	  sample	  buffer	  (40%	  glycerol,	  8%	  SDS,	  .25M	  Tris-­‐HCl	  pH	  6.8)	  and	  boiled	  for	  5	  minutes	  before	  being	  stored	  at	  -­‐80°C.	  Samples	  were	  sent	  to	  MD	  Anderson	  RPPA	  Core	  Facility,	  where	  the	  samples	  were	  diluted	  and	  added	  to	  nitrocellulose-­‐coated	  slides.	  Antibodies,	  using	  the	  tyramide	  amplification	  method,	  tag	  proteins	  on	  the	  slide	  and	  then	  the	  slide	  is	  scanned	  on	  a	  flatbed	  scanner.	  Detailed	  protocol	  and	  analysis	  completed	  by	  MD	  Anderson	  can	  be	  found	  on	  http://www.mdanderson.org/education-­‐and-­‐research/resources-­‐for-­‐professionals/scientific-­‐resources/core-­‐facilities-­‐and-­‐services/functional-­‐proteomics-­‐rppa-­‐core/education-­‐and-­‐references/index.html.	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Generating	  RT-­‐4	  cell	  lines	  that	  are	  resistant	  to	  FGFR	  inhibitors	  BGJ398	  and	  Ponatinib	  
	   To	  generate	  RT-­‐4	  cell	  lines	  resistant	  to	  FGFR	  inhibitors,	  we	  first	  had	  to	  determine	  at	  what	  drug	  concentrations	  the	  parental	  cell	  line	  was	  sensitive	  to	  BGJ398	  and	  Ponatinib.	  The	  parental	  cell	  lines	  were	  plated	  in	  three	  100mm	  dishes	  and	  each	  was	  treated	  with	  DMSO	  (control),	  5uM	  BGJ398	  or	  1.5uM	  Ponatinib	  for	  24	  hours.	  Western	  blot	  analysis	  showed	  a	  decrease	  of	  pFGFR3	  and	  pFRS2	  in	  the	  parental	  RT-­‐4	  cell	  lines	  that	  were	  treated	  with	  the	  inhibitors.	  α/β	  Tubulin	  was	  used	  to	  verify	  that	  the	  proteins	  were	  loaded	  in	  equal	  amounts	  (Figure	  1).	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After	  determining	  that	  BGJ398	  and	  Ponatinib	  inhibited	  the	  phosphorylation	  of	  FGFR3,	  we	  next	  sought	  to	  generate	  and	  prove	  resistance	  to	  inhibitors.	  Two	  sets	  of	  parental	  RT-­‐4	  cell	  lines	  were	  treated	  with	  either	  50nM	  BGJ398	  or	  25nM	  Ponatinib	  based	  on	  published	  IC50	  values	  and	  the	  IC50	  values	  of	  our	  initial	  cell	  viability	  curves	  of	  the	  parental	  cells	  lines	  treated	  with	  the	  inhibitors.	  The	  concentrations	  of	  the	  inhibitors	  were	  continually	  increased	  over	  an	  eight	  month	  period	  until	  the	  concentrations	  reached	  5uM	  BGJ398	  and	  1.5uM	  Ponatinib.	  Cell	  viability	  curves	  showed	  a	  separation	  between	  the	  parental	  cell	  lines	  and	  treated	  cell	  lines	  indicating	  a	  decrease	  in	  sensitivity	  to	  the	  inhibitors,	  which	  provided	  evidence	  for	  resistance	  (Figure	  2).	  For	  example,	  the	  IC50	  of	  the	  parental	  cell	  line	  is	  approximately	  150nM	  Ponatinib,	  but	  in	  the	  1.5uM	  Ponatinib	  resistant	  cell	  line	  the	  IC50	  is	  approximately	  2uM	  Ponatinib.	  Similarly,	  the	  IC50	  of	  the	  parental	  cell	  line	  is	  approximately	  100nM	  BGJ398,	  but	  in	  the	  5uM	  BGJ398	  resistant	  cell	  line	  the	  IC50	  is	  7uM	  BGJ398	  (Figure	  2).	  	  In	  addition	  to	  increased	  cell	  viability,	  the	  resistant	  cell	  lines	  showed	  a	  change	  in	  cellular	  morphology	  compared	  to	  the	  parent.	  The	  parental	  cells	  have	  a	  clustered,	  colony	  morphology,	  while	  both	  resistant	  cell	  lines	  appear	  to	  have	  a	  more	  spindle-­‐shaped	  morphology	  and	  expand	  across	  the	  plate	  more	  uniformly	  compare	  to	  the	  parental	  cell	  line	  (Figure	  3).	  Changes	  in	  cellular	  morphology	  could	  be	  representing	  an	  underlying	  change	  in	  protein	  expression	  either	  at	  the	  DNA,	  RNA,	  or	  protein	  level.	  
	  
Using	  RPPA	  analysis	  to	  determine	  candidate	  resistance	  mechanisms	  	   To	  evaluate	  potential	  mechanisms	  for	  the	  acquired	  resistance,	  we	  used	  RPPA	  analysis	  to	  look	  at	  a	  broad	  picture	  of	  protein	  expression	  in	  both	  the	  parental	  and	  resistant	  cell	  lines.	  	  After	  it	  was	  determined	  that	  the	  separation	  on	  the	  viability	  curve	  between	  the	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parent	  and	  the	  resistant	  cell	  lines	  was	  two	  logarithmic	  fold	  difference,	  the	  parental	  and	  two	  resistant	  cell	  lines	  were	  treated	  with	  either	  DMSO	  or	  FGFR	  inhibitors	  for	  24	  hours	  and	  triplicate	  samples	  were	  harvested	  and	  proteins	  were	  isolated	  and	  sent	  to	  MD	  Anderson	  for	  RPPA	  testing	  and	  analysis	  of	  over	  200	  proteins	  (Figure	  4).	  We	  then	  narrowed	  the	  list	  of	  candidate	  proteins	  by	  filtering	  out	  those	  with	  less	  than	  a	  20%	  upregulation	  or	  downregulation	  fold	  change.	  From	  that	  list	  we	  considered	  only	  those	  proteins	  with	  a	  q-­‐value	  of	  less	  than	  .05,	  giving	  us	  96	  significant	  proteins	  from	  the	  Ponatinib	  resistant	  cell	  line	  and	  88	  significant	  proteins	  from	  the	  BGJ398	  resistant	  cell	  line.	  Both	  the	  Ponatinib	  and	  BGJ398	  resistant	  cell	  lines	  showed	  an	  upregulation	  in	  the	  Akt,	  MAPKinase,	  and	  PI3-­‐Kinase	  pathways	  (Figure	  5).	  	   In	  an	  attempt	  to	  find	  a	  possible	  resistant	  mechanism	  to	  FGFR	  inhibitors,	  we	  analyzed	  RPPA	  data	  from	  other	  cancer	  cell	  lines	  with	  resistance	  to	  FGFR	  inhibitors.	  Simultaneously,	  in	  our	  lab	  two	  additional	  cancer	  cell	  lines,	  DMS114	  (lung	  cancer	  with	  FGFR1	  amplification)	  and	  RT-­‐112	  (bladder	  cancer	  with	  FGFR3	  amplification	  and	  fusion),	  became	  resistant	  to	  BGJ398	  and	  their	  proteins	  were	  analyzed	  using	  RPPA	  testing	  and	  analysis.	  All	  significant	  proteins,	  based	  on	  q-­‐values	  and	  fold	  changes,	  were	  cross-­‐referenced	  between	  the	  four	  resistant	  cell	  lines.	  8	  of	  the	  significant	  proteins	  found	  in	  the	  resistant	  cell	  lines	  interact	  with	  the	  PI3K	  and	  STAT	  pathways,	  which	  are	  downstream	  targets	  of	  FGFR	  signaling	  (Figure	  6).	  	  
Using	  Western	  blot	  analysis	  to	  verify	  candidates	  from	  RPPA	  data	  	  We	  used	  Western	  blot	  analysis	  in	  addition	  to	  RPPA	  analysis	  to	  verify	  upregulated	  pathways	  found	  in	  RPPA	  and	  to	  assess	  changes	  in	  specific	  proteins	  relevant	  to	  FGFR	  signaling	  that	  could	  not	  be	  studied	  by	  RPPA	  analysis,	  such	  as	  FGFR3	  and	  FRS2.	  	  There	  is	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little	  difference	  in	  phosphorylation	  of	  FGFR3	  between	  the	  parental	  cell	  line	  and	  the	  resistant	  cell	  line,	  even	  though	  the	  resistant	  cell	  lines	  are	  being	  treated	  with	  FGFR	  inhibitors.	  While	  the	  parental	  and	  5uM	  BGJ398	  resistant	  cell	  line	  have	  similar	  pFRS2	  expression,	  the	  pFRS2	  is	  downregulated	  in	  the	  1.5uM	  Ponatinib	  resistant	  cell	  line	  (Figure	  
7).	   Next,	  we	  performed	  Western	  blot	  analysis	  to	  verify	  the	  results	  observed	  from	  the	  RPPA	  analysis	  of	  certain	  upregulated	  pathways.	  The	  PI3K	  pathway	  is	  part	  of	  FGFR	  signaling,	  and	  the	  RPPA	  revealed	  many	  upregulated	  proteins	  across	  the	  four	  resistant	  cell	  lines	  within	  this	  pathway.	  These	  proteins	  include,	  but	  are	  not	  limited	  to	  pAkt	  S473,	  pAkt	  T308,	  pGSK	  3β,	  and	  pGSK	  3α/β.	  The	  most	  significant	  changes	  in	  phosphorylation	  of	  the	  resistant	  cell	  lines	  when	  compared	  to	  the	  parental	  can	  be	  seen	  in	  pAkt	  S473,	  pGSK	  3β,	  and	  pGSK	  3α/β.	  pAkt	  S473,	  pGSK	  3β,	  and	  pGSK	  3α/β	  appears	  to	  be	  more	  phosphorylated	  in	  5uM	  BGJ398	  resistant	  cell	  line	  when	  compared	  to	  the	  1.5uM	  Ponatinib	  resistant	  cell	  line	  (Figure	  8).	  With	  RPPA	  analysis	  showing	  upregulated	  proteins	  and	  supporting	  Western	  blot	  analysis,	  we	  decided	  to	  assess	  the	  effects	  of	  inhibiting	  Akt	  activity	  with	  GSK2141795,	  a	  clinical	  grade	  Akt	  inhibitor,	  in	  the	  5uM	  BGJ398	  resistant	  cell	  line.	  	  
Use	  of	  a	  GSK2141795	  to	  inhibit	  Akt	  activity	  in	  RT-­‐4	  5uM	  BGJ398	  resistant	  cell	  lines	  	  	  We	  designed	  an	  experiment	  that	  not	  only	  compared	  the	  effect	  of	  GSK2141795	  on	  the	  parental	  cell	  line	  versus	  the	  resistant	  cell	  line,	  but	  also	  the	  effect	  of	  GSK2141795	  when	  used	  in	  combination	  with	  BGJ398	  on	  the	  resistant	  cell	  line.	  We	  treated	  the	  parental	  and	  the	  5uM	  BGJ398	  resistant	  cell	  lines	  with	  a	  variety	  of	  BGJ398	  and	  a	  variety	  of	  GSK2141795	  concentrations	  ranging	  from	  1nM	  to	  10uM.	  The	  5uM	  BGJ398	  resistant	  cell	  line	  was	  also	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treated	  with	  a	  combination	  of	  500nM	  GSK2141795	  with	  various	  concentrations	  of	  BGJ398	  and	  1.5uM	  GSK2141795	  with	  various	  concentrations	  of	  BGJ398.	  There	  was	  little	  effect	  on	  the	  parental	  cell	  line	  when	  GSK2141795	  was	  administered	  in	  various	  concentrations,	  which	  is	  consistent	  with	  what	  we	  expected	  to	  see,	  because	  FGFR	  can	  use	  a	  variety	  of	  pathways	  other	  than	  Akt.	  The	  parental	  cell	  line	  treated	  with	  GSK2141795	  had	  an	  IC50	  of	  10uM.	  We	  saw	  a	  decrease	  in	  cell	  viability	  in	  the	  5uM	  BGJ398	  resistant	  cell	  line	  when	  GSK2141795	  is	  administered,	  with	  an	  IC50	  of	  approximately	  1.5uM.	  However	  we	  saw	  an	  even	  larger	  decrease	  in	  cell	  viability	  when	  BGJ398	  and	  GSK2141795	  are	  used	  in	  combination,	  with	  an	  IC50	  of	  10nM	  BGJ398	  when	  treated	  in	  combination	  with	  500nM	  GSK2141795	  and	  an	  IC50	  of	  1nM	  BGJ398	  when	  treated	  in	  combination	  with	  1.5uM	  GSK2141795	  (Figure	  9).	  The	  difference	  between	  cell	  viability	  of	  the	  parental	  cell	  line	  and	  resistant	  cell	  line	  when	  exposed	  to	  GSK2141795	  provides	  evidence	  of	  changes	  in	  protein	  dependence	  after	  chronic	  exposure	  to	  an	  inhibitor.	  The	  effectiveness	  of	  GSK2141795	  on	  the	  resistant	  cell	  line	  verifies	  the	  use	  of	  RPPA	  to	  suggest	  resistant	  mechanisms	  and	  the	  ability	  to	  use	  a	  second	  inhibitor	  to	  reduce	  cell	  viability	  on	  a	  resistant	  cell	  line.	  	  
Discussion	  
	  Although	  tyrosine	  kinase	  inhibitors	  may	  represent	  a	  new	  focused	  treatment	  for	  cancer,	  many	  patients	  develop	  resistance	  to	  the	  inhibitors	  over	  time	  despite	  initial	  responses	  or	  benefits.	  Some	  inhibitors’	  resistance	  patterns	  have	  been	  studied	  heavily,	  such	  as	  ABL1,	  EGFR,	  BRAF,	  and	  ALK,	  but	  there	  has	  been	  little	  research	  done	  on	  acquired	  drug	  resistance	  for	  FGFR	  since	  it	  is	  a	  novel	  target.	  We	  have	  demonstrated	  the	  ability	  to	  produce	  FGFR	  resistant	  cell	  lines	  over	  a	  period	  of	  months	  and	  utilized	  RPPA	  analysis	  to	  study	  a	  variety	  of	  possible	  resistance	  mechanisms.	  After	  cross-­‐referencing	  RPPA	  data	  from	  four	  different	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resistant	  cell	  lines,	  we	  were	  able	  to	  narrow	  our	  focus	  to	  resistance	  mechanisms	  within	  the	  FGFR	  pathway.	  Using	  western	  blot	  analysis,	  we	  hypothesized	  that	  multiple	  proteins	  within	  Akt	  pathway	  were	  upregulated.	  With	  this	  information,	  we	  inhibited	  the	  Akt	  pathway	  and	  showed	  that	  a	  combination	  therapy	  was	  more	  effective	  than	  the	  individual	  inhibitors.	  	   There	  are	  many	  pathways,	  such	  as	  the	  Akt	  pathway,	  within	  a	  cell	  that	  could	  lead	  to	  a	  resistance	  mechanism.	  RPPA	  analysis	  could	  be	  a	  useful	  tool	  for	  identifying	  mechanisms	  of	  resistance	  after	  treatment	  with	  an	  inhibitor.	  It’s	  low	  cost,	  quick	  turnaround,	  and	  high	  output	  are	  ideal	  to	  analysis	  a	  wide	  range	  of	  protein	  pathways	  in	  the	  cell.	  Suggestion	  of	  a	  resistance	  pathway	  and	  not	  a	  specific	  protein	  allows	  for	  the	  opportunity	  to	  use	  a	  variety	  of	  inhibitors	  found	  within	  a	  pathway.	  The	  analysis	  can	  be	  easily	  compared	  over	  multiple	  samples.	  Although	  RPPA	  is	  a	  valuable	  tool	  to	  narrow	  down	  the	  path	  of	  resistance,	  it	  has	  its	  limitations.	  Some	  proteins	  that	  are	  known	  to	  drive	  cancer	  are	  found	  in	  the	  extracellular	  membrane,	  which	  are	  not	  easily	  extracted	  from	  the	  cell	  membrane	  and	  are	  not	  tested	  for	  in	  RPPA	  analysis.	  It	  is	  important	  to	  verify	  the	  results	  found	  and	  study	  missing	  components	  in	  RPPA	  analysis	  with	  some	  other	  form	  of	  analysis,	  such	  as	  Western	  blot,	  DNA	  sequencing,	  or	  RNA	  sequencing.	  Although	  RPPA	  analysis	  and	  Western	  blot	  analysis	  has	  provided	  the	  theory	  of	  Akt	  resistance,	  there	  are	  more	  experiments	  that	  need	  to	  be	  completed	  to	  convince	  us	  of	  Akt’s	  involvement	  in	  resistance.	  We	  will	  be	  completing	  cell	  viability	  curves	  using	  Akt	  siRNA	  to	  analyze	  the	  effect	  of	  a	  specific	  Akt	  knockdown.	  In	  addition	  to	  cell	  viability	  curves,	  we	  will	  also	  be	  completing	  Western	  blot	  analysis	  using	  Akt	  siRNA	  and	  the	  Akt	  inhibitor	  GSK2141795	  to	  verify	  that	  both	  are	  inhibiting	  Akt	  and	  not	  causing	  a	  decrease	  in	  cell	  viability	  simply	  through	  toxicity.	  Using	  the	  resistant	  cell	  lines,	  we	  will	  also	  perform	  wound	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healing	  assays	  to	  identify	  changes	  in	  cell	  migration	  between	  the	  parental	  cell	  line,	  resistant	  cell	  line,	  and	  resistant	  cell	  lines	  treated	  with	  Akt	  siRNA.	  In	  addition	  to	  these	  experiments,	  we	  will	  be	  studying	  other	  researchers	  work	  on	  the	  Akt	  pathway.	  Several	  papers	  have	  demonstrated	  that	  proteins	  within	  the	  Akt	  pathway	  contribute	  to	  resistance	  and	  changes	  in	  cellular	  morphology.7,	  8,	  9,	  10	  In	  Grygielewicz	  et	  al.’s	  paper,	  “Epithelial-­‐mesenchymal	  transition	  confers	  resistance	  to	  selective	  FGFR	  inhibitors	  in	  SNU-­‐16	  gastric	  cancer	  cells,”	  described	  that	  resistance	  using	  FGFR	  inhibitors	  has	  a	  common	  pathway	  of	  resistance	  that	  is	  independent	  of	  the	  inhibitor	  itself.	  They	  discovered	  upregulation	  in	  the	  Akt,	  ERK,	  STAT3,	  and	  HER2	  pathways.7	  Thorne	  et	  al.	  describes	  the	  effect	  that	  GSK-­‐3	  can	  have	  on	  a	  variety	  of	  kinase	  inhibitors.9	  Because	  of	  the	  prevalence	  of	  proteins	  in	  the	  Akt	  pathway’s	  contribution	  to	  resistance,	  many	  inhibitors	  have	  been	  designed	  to	  target	  this	  pathway.	  This	  could	  be	  important	  for	  potential	  combination	  therapy	  for	  patients	  in	  the	  future.	  	   This	  study	  highlights	  the	  importance	  of	  understanding	  secondary	  resistance	  mechanisms.	  While	  suggesting	  a	  technique	  to	  find	  resistance	  patterns	  within	  patients,	  we	  were	  also	  able	  to	  identify	  a	  common	  secondary	  resistance	  pathway	  with	  FGFR	  dependent	  cancers.	  In	  the	  future,	  this	  could	  narrow	  the	  search	  for	  resistance	  patterns	  if	  we	  find	  a	  common	  pathway	  within	  FGFR	  dependent	  cell	  lines	  and	  administer	  combination	  therapies	  earlier	  in	  treatment	  plans.	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Figures	  and	  Tables	  
	  Figure	  1	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Figure	  3:	  (a)	  Morphology	  of	  parental	  cell	  line.	  (b)	  Morphology	  of	  1.5uM	  Ponatinib	  resistant	  cell	  line.	  (c)	  Morphology	  of	  5uM	  BGJ398	  resistant	  cell	  line.	  	  Figure	  4	  (a)	  
	  	  	  	  (b)	  
	  
Figure	  4:	  (a)	  Heat	  map	  of	  RPPA	  analysis	  of	  proteins	  from	  control	  and	  1.5uM	  Ponatinib	  resistant	  RT-­‐4	  cell	  line.	  (b)	  Heat	  map	  of	  RPPA	  analysis	  of	  proteins	  from	  control	  and	  5uM	  BGJ398	  resistant	  RT-­‐4	  cell	  line.	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  Figure	  5	  
(a)	  































Figure	  5(a)	  Heat	  map	  with	  proteins	  of	  20%	  fold	  change	  upregulated	  and	  downregulated	  proteins,	  according	  to	  RPPA	  analysis,	  in	  the	  1.5uM	  Ponatinib	  resistant	  cell	  line.	  (b)	  Heat	  map	  with	  top	  20%	  fold	  change	  upregulated	  and	  downregulated	  proteins,	  according	  to	  RPPA	  analysis,	  in	  the	  5uM	  BGJ398	  resistant	  cell	  line.	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  Figure	  6	  
(a)	  
	  	  Significant	  Protein	  Changes	  Found	  in	  3	  Cell	  Lines	  Akt_pS473	  Akt_pT308	  Cyclin-­‐B1	  eEF2K	  GSK-­‐3ab_pS21_S9	  GSK-­‐3b_pS9	  Stat3_pY705	  Stat5a	  TSC1	  YAP_pS127	   	  	  	  	  	  	  	  
RT-­‐4	  	  BGJ398	  
RT-­‐112	  	  BGJ398	   DMS114	  	  BGJ398	  12	  
10	   25	  30	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Figure	  6:(a)	  Number	  of	  proteins,	  with	  at	  least	  20%	  fold	  change	  and	  sorted	  by	  q	  values,	  in	  common	  between	  three	  FGFR	  resistant	  cell	  lines,	  RT-­‐112	  5uM	  BGJ398,	  DMS114	  3uM	  BGJ398	  and	  RT-­‐4	  5uM	  BGJ398	  according	  to	  RPPA	  analysis.	  List	  of	  proteins	  with	  significant	  
RT-­‐4	  	  Ponatinib	  
12	  RT-­‐112	  	  BGJ398	   DMS114	  	  BGJ398	  
30	  27	   8	  
Significant	  Protein	  Changes	  Found	  in	  3	  Cell	  Lines	   Cyclin-­‐B1	    eEF2K	   GSK-­‐3ab_pS21_S9	    GSK-­‐3b_pS9	    Stat3_pY705	    Stat5a	    TSC1	    YAP_pS127	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fold	  changes	  and	  sorted	  by	  q	  values	  found	  in	  the	  3	  resistant	  cell	  lines.	  (b)	  Number	  of	  proteins,	  with	  at	  least	  20%	  fold	  change	  and	  sorted	  by	  q	  values,	  in	  common	  between	  three	  FGFR	  resistant	  cell	  lines,	  RT-­‐112	  5uM	  BGJ398,	  DMS114	  3uM	  BGJ398	  and	  RT-­‐4	  1.5uM	  Ponatinib	  according	  to	  RPPA	  analysis.	  List	  of	  proteins	  with	  significant	  fold	  changes	  and	  sorted	  by	  q	  values	  found	  in	  the	  3	  resistant	  cell	  lines.	  
	  Figure	  7	  
	   	  
Figure	  7:	  The	  parental	  cell	  line	  was	  treated	  with	  DMSO,	  the	  5uM	  BGJ398	  resistant	  cell	  line	  was	  treated	  with	  5uM	  BGJ398,	  and	  the	  1.5uM	  Ponatinib	  resistant	  cell	  line	  was	  treated	  with	  1.5uM	  Ponatinib	  for	  24	  hours.	  The	  first	  Western	  blot	  on	  the	  left	  presents	  minimal	  reactivation	  of	  the	  pFGFR3	  pathway	  in	  resistant	  cell	  lines.	  The	  first	  Western	  blot	  on	  the	  right	  demonstrates	  no	  reactivation	  within	  the	  Ponatinib	  resistant	  cell	  line	  and	  minimal	  reactivation	  within	  the	  BGJ398	  resistant	  cell	  line.	  GAPDH	  is	  a	  protein	  loading	  control.	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  Figure	  8	  
	  
Figure	  8:	  Western	  blot	  analysis	  showing	  changes	  in	  protein	  concentration	  between	  resistant	  cell	  lines	  and	  parental	  cell.	  Proteins	  were	  chosen	  based	  on	  RPPA	  analysis	  that	  suggested	  changes	  in	  PI3K	  and	  STAT	  pathway.	  The	  parental	  cell	  line	  was	  treated	  with	  DMSO,	  the	  5uM	  BGJ398	  resistant	  cell	  line	  was	  treated	  with	  5uM	  BGJ398,	  and	  the	  1.5uM	  Ponatinib	  resistant	  cell	  line	  was	  treated	  with	  1.5uM	  Ponatinib	  for	  24	  hours.	  Both	  STAT3	  and	  STAT5,	  proteins	  in	  the	  STAT	  pathway,	  are	  downstream	  targets	  of	  FGFR3	  and	  are	  upregulated	  in	  the	  BGJ398	  resistant	  cell	  line	  when	  compared	  to	  the	  parental	  cell	  line.	  pAkt	  S473,	  pAkt	  T308,	  pGSK-­‐3α/β,	  pGSK-­‐3β,	  proteins	  in	  the	  PI3K,	  are	  downstream	  targets	  of	  FGFR3	  and	  are	  upregulated	  in	  both	  resistant	  cell	  lines	  when	  compared	  to	  the	  parental	  cell	  line.	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  Figure	  9	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  cell	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